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Background: Diabetes in pregnancy carries an increased risk of adverse pregnancy outcomes for both the mother
and foetus, but it also provides an excellent early opportunity for intervention in the life course for both mother
and baby. In the context of the escalating epidemic of chronic diseases among Indigenous Australians, it is vital
that this risk is reduced as early as possible in the life course of the individual. The aims of the PANDORA Study are
to: (i) accurately assess rates of diabetes in pregnancy in the Northern Territory (NT) of Australia, where 38% of
babies are born to Indigenous mothers; (ii) assess demographic, clinical, biochemical, anthropometric, socioecono-
mic and early life development factors that may contribute to key maternal and neonatal birth outcomes
associated with diabetes in pregnancy; and (iii) monitor relevant post-partum clinical outcomes for both the
mothers and their babies.
Methods/Design: Eligible participants are all NT women with diabetes in pregnancy aged 16 years and over.
Information collected includes: standard antenatal clinical information, diagnosis and management of diabetes in
pregnancy, socio-economic status, standard clinical birth information (delivery, gestational age, birth weight, adverse
antenatal and birth outcomes). Cord blood is collected at the time of delivery and detailed neonatal anthropometric
measurements performed within 72 hours of birth. Information will also be collected regarding maternal post-
partum glucose tolerance and cardio-metabolic risk factor status, breastfeeding and growth of the baby up to
2 years post-partum in the first instance.
Discussion: This study will accurately document rates and outcomes of diabetes in pregnancy in the NT of
Australia, including the high-risk Indigenous Australian population. The results of this study should contribute to
policy and clinical guidelines with the goal of reducing the future risk of obesity and diabetes in both mothers
and their offspring.
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The antecedents of non-communicable diseases are early
in life, beginning in utero. In order to address the escal-
ating epidemic of chronic diseases among Indigenous
Australians [1], we need to reduce risk as early as pos-
sible in the life of an individual. Diabetes in pregnancy
(DIP) is associated with increased risk of adverse preg-
nancy outcomes for both the mother and the child, but
also provides an early opportunity for intervention in
the life of both mother and baby.
Diabetes in pregnancy includes gestational diabetes
mellitus (GDM) and pre-existing diabetes (type 1 and
type 2) in pregnancy. Rates of both pre-existing diabetes
in pregnancy and GDM are higher in Indigenous
Australian women compared to the general Australian
population despite a younger age of giving birth [2,3].
Particularly striking are the high rates of pre-existing
type 2 diabetes in pregnancy among Indigenous Austra-
lian women, with rates over ten times greater than those
reported in the general Australian population [4]. The
recent increase in T2DM in pregnancy among Indigen-
ous Australian women is of concern as it is associated
with significantly higher risk (compared to GDM) for
outcomes such as stillbirth and congenital malforma-
tions [3,5-7].
Large international studies have reported the adverse
perinatal and obstetric outcomes associated with hyper-
glycaemia in pregnancy [8] and the beneficial perinatal
outcomes that result from good blood glucose control in
pregnancy, including lower rates of babies born large for
gestational age, pre-eclampsia, shoulder dystocia and
birth trauma [9]. Diabetes in pregnancy has also been as-
sociated with increased future risk of other chronic dis-
eases, for both the mother and baby. Future risk of type
2 diabetes in the mother is increased seven-fold follow-
ing a pregnancy complicated by GDM [10]. Canadian
data report very high future risk for Indigenous women:
over 70% of women developed type 2 diabetes within
4 years of GDM diagnosis [11]. Children of mothers with
DIP are more likely to be obese in adolescence [12], and
have diabetes in early adulthood, with the rates of type 2
diabetes substantially higher in offspring of mothers with
pre-existing DIP than those of mothers with GDM or
without DIP [13].
We have developed a partnership between researchers,
health care providers and policy organisations in the
Northern Territory (NT), Australia, to address the issue
of DIP in the high-risk population of the NT. The
partnership includes a detailed research component:
Pregnancy And Neonatal Diabetes Outcomes in Remote
Australia – The PANDORA Study. The NT covers a
large geographical area (1.35 million square kilometres),
but has a relatively small population (230,000), with a
population density of 0.2 people/km2 [14]. From 2001 to2005, the average annual number of births in the NT
was 3566, of whom 38% were born to Indigenous
mothers [15].
Aims
The aims of The PANDORA Study are:
1) To accurately assess the rates of diabetes in
pregnancy in the Northern Territory, Australia.
2) To report demographic, clinical, biochemical,
anthropometric and socioeconomic factors that may
contribute to key maternal and neonatal outcomes
associated with DIP in the NT.
3) To monitor relevant clinical outcomes for both the
mothers and their babies, and provide reliable
information around future health risk for the NT.
Methods/Design
Study design and overview
This study will be the research arm of the larger NT
DIP Partnership Program. The NT DIP Partnership aims
to: (i) improve systems and service delivery for all
women in the NT with DIP, in order to improve out-
comes for mother and baby; (ii) reduce the gap between
evidence and practice in relation to screening, manage-
ment and post-partum follow-up of women with DIP
and their baby; (iii) establish systems that enable close
monitoring of relevant clinical outcomes for mothers
and babies. These aims will be achieved by: (i) establish-
ing an NT DIP clinical register; (ii) developing and
evaluating an appropriate model of care for DIP; (iii) in-
stituting early universal detection of DIP; (iv) enhancing
capacity of health care professionals in identifying and
managing DIP; and (v) delivering a detailed research
component to accurately assess antenatal characteristics
and neonatal outcomes of DIP. The research component
is The PANDORA Study and is described here.
Setting & location
Participants will be residents of the Northern Territory,
Australia. Participation in the study is facilitated through
the following hospitals, Royal Darwin Hospital, Katherine
District Hospital, Gove District Hospital, Alice Springs
Hospital, Tennant Creek Hospital; Aboriginal Medical
Services, Danila Dilba Health Services, Bagot Community
Health Centre, Wurli Wurlinjang, Sunrise Health Service
Aboriginal Cooperation, Miwatj Health Aboriginal Cor-
poration, Central Australian Aboriginal Congress, Anyin-
ginyi Health Aboriginal Corporation, Pintubi Homelands,
Ampilatawatja Health Care Centre, Nganampa Health
Council, Amoonguna; and health facilities, Healthy Living
NT and NT Department of Health remote. Consultation
with other Aboriginal Medical Services in the NT regard-
ing their participation in the study is ongoing.
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Potential participants will be all NT women (Indigenous
and non-Indigenous) with any type of diabetes in preg-
nancy (type 1 diabetes mellitus, type 2 diabetes mellitus
and gestational diabetes mellitus). Participants are aged
16 years and above, from urban, rural and remote re-
gions of the NT. A NT DIP Clinical Register was estab-
lished in 2011–2012 as part of the larger NT DIP
Partnership Program. Women with DIP from the NT are
referred to the register and information maintained for
clinical use by both specialist and primary health care
teams. The register data are collected primarily by the
senior diabetes nurse educators at Royal Darwin Hos-
pital and Alice Springs Hospital, with additional referrals
received from diabetes nurse educators at other sites, in-
cluding Healthy Living NT, Katherine District Hospital
and Gove District Hospital. Once the woman is in con-
tact with either the specialist team or the research team,
they are invited to participate in the research study
(PANDORA).
Funding
Major funding is provided by the National Health and
Medical Research Council of Australia (NHMRC Part-
nership Project Grant #1032116). Additional support
(including pilot funding) was received from NHMRC
Program Grant #631947.
Ethics
The study is approved by the joint Menzies School of
Health Research – Northern Territory Department of
Health Human Research Ethics Committee, including
the Aboriginal sub-committee. The study is also ap-
proved by the Central Australian Human Research
Ethics Committee.
Staff
Six research staff are employed over the course of the
study. Two post-graduate research students are participat-
ing in the study and are substantially involved in data col-
lection. All research staff members have prior health
qualifications and experience: all are registered nurses, of
whom two are also diabetes educators, and four are mid-
wives. The post-graduate research students are a specialist
endocrinologist and a paediatric endocrinologist.
The Partnership involves considerable in-kind contri-
bution from all partners: NT Department of Health,
AMSANT, Baker IDI and Healthy Living NT (primarily
health professional staff time and travel costs).
Consent
Potential participants have face-to-face discussion with a
study staff member, are provided with visually enhanced
written information about the study and given anopportunity to ask questions. An interpreter is employed
to explain study information when required. Those who
indicate interest in participating are then asked to
complete written consent. Consent is obtained using the
NHMRC Guidelines for Ethical Conduct in Aboriginal
and Torres Strait Islander Health Research. All partici-
pants are informed that their participation is voluntary,
that they can refuse or withdraw from participating, they
need give no reason or justification for their decision to
withdraw, and that it would not affect their medical care.
A parent or guardian is asked to sign the form in
addition to the participant if the participant is under
18 years old. Participants are asked to give separate con-
sent for various elements of the study, including cord
blood collection, baby body measurements, question-
naire and collecting further information from their med-
ical records. They are informed that their cord blood
samples will be stored at Menzies School of Health
Research for 25 years and asked whether their cord
blood samples could be used for future studies related to
diabetes and cardiovascular disease.
Screening criteria for gestational diabetes
The diagnosis of GDM is based on the Australian
Diabetes in Pregnancy Society (ADIPS) guidelines, which
changed during the course of The PANDORA Study.
Prior to 2012, guidelines were that all pregnant women
be screened routinely for GDM at 24–28 weeks gesta-
tion with a 50 g glucose challenge test (GCT). A positive
cut-off value after 1 hr in GCT was 7.8 mmol/L plasma
glucose for the 50 g load. Women with a positive GCT
proceeded to have a fasting 75 g oral glucose tolerance
test (OGTT) for which the diagnostic criteria was one
or more of the following values: fasting glucose ≥
5.5 mmol/L or 2-h plasma glucose ≥ 8.0 mmol/L [16].
From 2012, GDM was diagnosed based on new ADIPS
recommendations [17] of universal OGTT (without an
initial GCT), with an increase in implementation of
these guidelines towards the end of 2013. From the end
of 2013, GDM was diagnosed by one or more of the fol-
lowing values from the 75gm OGTT: fasting glucose ≥
5.1 mmol/L, 1-h plasma glucose ≥ 10.0 mmol/L or 2-h
plasma glucose ≥ 8.5 mmol/L [17]. There was an overlap
period for approximately 2 years following the introduc-
tion of the new guidelines, during which time women
were diagnosed with GDM by either of the above
guidelines. Local guidelines (Minymaku Kutju Tjukurpa
Women’s Business Manual 4th edition [18]) are used in
conjunction with the above guidelines and recommend
HbA1c and random glucose at first antenatal visit in
women at high risk of undiagnosed type 2 diabetes
(all Indigenous Australian women). Consideration for
early 75gm OGTT in these high risk women was recom-
mended in the NT according to IADPSG guidelines [19].
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2 diabetes, first diagnosed in pregnancy, are included in
the group of women classified as GDM for the purposes of
analysis. A clinical diagnosis of likely undiagnosed type 2
diabetes was based on one of the following at first
antenatal visit: fasting glucose ≥7.0 mmol/l, 2 hour glucose
≥11.1 mmol/l, HbA1c ≥6.5% [19].
Data collection techniques
Once written consent is attained for the research study,
the relevant clinical information for participants is trans-
ferred from the clinical register to the research study
database. The following information is collected:
(i) Antenatal data collected by the clinical team:
a. Assessment of antenatal health: weight (in first
and late third trimester), height, blood pressure,
gravidity and parity, oral glucose tolerance test,
HbA1c (when done), haemoglobin, serum
creatinine, urine albumin-creatinine ratio, type
of diabetes in pregnancy (GDM, type 1 diabetes,
type 2 diabetes, or likely pre-existing type 2 dia-
betes), estimated date of delivery (ultrasound)
b. Additional standard antenatal care data is
collected by the clinical team, and collated peri-
partum by the research team: management of
DIP (oral agents, use and type of insulin), other
medications, antenatal incidence of maternal
hypoglycaemia (mild/severe), hospitalisation
before delivery, other comorbidities, obstetric
antenatal complications (e.g. antepartum haemor-
rhage, placenta praevia), antenatal mode of care
and specialist involvement, vitamin D status,
physical activity, dietary habits and Edinburgh
depression scale score [20].
(ii) Further antenatal data collected by the research
team:
a. Assessment of socio-economic status and related
personal details by questionnaire: age, contact
details, hospital record number, maternal and
paternal ethnicity, first language, language spoken
at home, ethnicity of maternal and paternal
grandparents for Aboriginal and Torres Strait
Islander participants, income source, ever worked,
employment status, education level, housing ten-
ure, landlord type (government, private, other),
self-reported pre-pregnancy weight, pre-
conception medication and pre-conception care.
b. Medical history and medications- self report and
from medical records (where available) including
assessment of cigarette smoking, use of pituri
(chewing of wild tobacco plants), tobacco chew-
ing, alcohol and other recreational drugs used
during pregnancy, past medical history andsupplements/medications during pregnancy,
maternal and paternal family history of diabetes.
c. Maternal obstetric information: hypertension,
pre-eclampsia, eclampsia, ultrasound scan of
morphology, number of ultrasound scans for
growth assessment.
d. Additional questionnaires to assess stress and
depression were performed in a sub-study of par-
ticipants: Patient Health Questionnaire 9 (PHQ9)
and adapted PHQ9 [21]
(iii) Postnatal data collected by the research team
a. Neonatal information: location, birth date and
time, birth outcome, time to first breastfeed,
APGAR Score, shoulder dystocia, neonatal
obstetric trauma, severe adverse event (death,
delivery <32 weeks, prolonged hospitalisation
with >1 week special care nursery, condition
which results in significant disability/incapacity
or requires medical intervention to prevent
permanent damage), major and minor congenital
malformation, admission and length of stay to
special care nursery, neonatal hypoglycaemia,
hyperbilirubinaemia, phototherapy, exchange
transfusion, hypoxic ischaemic encephalopathy,
neonatal hypocalcaemia, meconium aspiration,
respiratory distress, gestational age at delivery.
Congenital malformations defined as: structural
abnormalities detected prior to birth by
ultrasound or at or soon after birth by clinical
examination, X-ray, or ultrasound and, in the
event of neonatal or perinatal death, by autopsy;
and classified as major if fatal, potentially life
threatening, likely to lead to serious handicap, or
likely to lead to major cosmetic defect.
b. Maternal obstetric information: mode of delivery,
labour complications (type of instrumental
delivery, third/fourth degree perineal tear,
postpartum haemorrhage, uterine rupture, foetal
distress, cord prolapse, manual removal of
placenta, meconium stained liquid and others),
need and reason for induction of labour,
indication for caesarean or operative vaginal
delivery.
c. At discharge: breastfeeding at discharge, type of
contraception planned, medications.
(iv) Neonatal anthropometric measurements
performed by the research team: neonates have
anthropometric measurements completed within
72 hours of birth. If measurements are unable to
be performed within 72 hours of birth, they may
be performed up to 120 hours of birth and
recorded as such. Neonatal anthropometric
measurements are conducted with a calibrated
scale for weight (Darwin: Ultracare electronic
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measuring board for length (Seca, Hamburg,
Germany), Holtain calipers (Holtain Ltd, Crosswell,
Pembrokeshire, United Kindgom) for skin fold
measurements, a measuring tape for
circumferences, and a metal anthropometer
(Scientific Martin Pelvimeter) for limb length. All
limb and skin fold measures are made on the left
side, except when the left limb is unavailable for
access (eg the neonate had intravenous therapy in
the left arm). For all measurements, the mean of
the two measurements was used, unless a third
measurement was taken (if the two measures
differed by more than the prescribed amount).
When a third measurement was taken, if two of
three measurements differed by less than the pre-
specified amount, the mean of those two was used,
otherwise the mean of all three was used [22].
a. A bare weight is obtained on a calibrated scale, and
recorded to the nearest 5 gram. This procedure is
repeated and recorded twice. A third measurement
is performed if the first two measurements are not
within 10 grams of each other.
b. Length is obtained on a standardized plastic
length board and recorded in centimetres. The
infant is positioned on its back so that the
vertebrae touch the base of the length board. The
crown of the head lies against the vertical end of
the length board. Keeping the infant’s head in the
proper position, the examiner uses the thumb of
his/her left hand and firmly presses the infant’s
chest into the base of the length board to ensure
that the spine is straight. The examiner then uses
his/her right hand to extend the legs straight.
When the infant’s body is positioned properly, the
examiner measures the length with the movable
foot board attached to the length board. Lengths
are obtained and recorded to the nearest 0.1 cm
at least twice. If lengths differ by more than
0.5 cm, a third length is taken and recorded.
c. Circumference of the head is measured with a
measuring tape, including the occipital
protuberance, measured while the baby is quiet.
d. Skinfold thickness assessment is performed at 3 sites.
Study staff were trained by a Clinical and Data
Coordinating Centre Staff member of the
Hyperglycaemia and Adverse Pregnancy Outcomes
(HAPO) Study, using the HAPO video and methods
[22,23]. The skin fold site is marked using a felt-tip
pen and each site is identified as follows: the triceps
skin fold is measured over the triceps, midway be-
tween the acromion and olecranon. The subscapular
skin fold is measured at the lower angle of the scap-
ula. The flank skin fold is measured in the mid-axillary line just above the crest of the ilium. The skin
fold is obtained by lifting the top layer of the skin at
the specific landmark with the thumb and the index
finger. While holding onto the skin, the calipers are
applied perpendicular to the fold, on the site marked.
While maintaining the grasp of the skinfold, the cali-
pers are released so that full tension is placed on the
skinfold. The dial is read to the nearest 0.1 mm,
30–45 seconds after the grip is fully released, or until
the reading has stabilized. Two readings are taken at
each site. A third reading is done if the two readings
differ by more than 0.5 mm.e. The following additional body composition measures
are performed in a detailed body-composition
sub-study of the larger PANDORA Study:
- Skin fold thickness assessment is performed at 2
additional sites: thigh and abdomen [24]. The
thigh skin fold is measured midway between the
crural fold and the large semilunar crease above
the patella when the leg is fully extended in the
longitudinal plane of the leg. The abdomen skin
fold is measured midway between the xiphoid
and the umbilicus on the nipple line.
- Circumferences of the chest (across the nipple
line), abdomen at the liver and umbilicus, and
mid-portion of the upper and lower extremities
are measured with a measuring tape.
- Lengths of the upper and lower limbs are
determined with a metal anthropometer.
(v) Cord blood collection:
A specimen of cord blood is obtained from all
neonates born to the study participants for analysis
of glucose, C-peptide, lipids, C-reactive protein,
interleukin-6, adiponectin and leptin. The specimen
is obtained by free drainage (free flow) of cord blood
or drawn by needle aspiration (puncture) from a
clamped segment of an umbilical vein. The specimen
is stored in a foam cooler for transport to the
hospital laboratory.(vi) Maternal follow-up information collected by re-
search team:Six week post partum oral glucose tolerance test
results for women with gestational diabetes, rates and
duration of breast feeding, assessment at 24 months of
metabolic and cardiovascular risk (adult health check),
use and mode of contraception, cigarette smoking,
weight, medications, subsequent pregnancy.(vii) Follow up of baby:
Any fatal event, identification of congenital
abnormalities beyond birth, significant medical
diagnoses, hospitalisation, growth at 1, 2,4, 6–8 and
15–18 months in the first instance. Additional
funding will be sought for follow-up of the baby and
mother beyond that detailed above.
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Collected cord blood samples are centrifuged for 10 mi-
nutes at 3000 revolutions per minute within 1–2 hours
of collection. The time between collection and centrifu-
gation is noted for all cord blood samples. Following
centrifugation, plasma is divided from the blood tube
ensuring no cells are transferred to sample vials.
Vials are transported on ice for storage in -70°C
freezers. Analysis of glucose and lipids are performed at
each centre as outlined in Table 1. Samples are stored
for analysis at a later date for: c-peptide, C-reactive pro-
tein, interleukin-6, adiponectin and leptin.
Sample size
All NT women with DIP, estimated to be 250–300 women/
year, are eligible for the study with the exception of those
aged <16 years. We expect that approximately 60% of these
women will consent to the research study. Consent of par-
ticipants for PANDORA commenced in November 2011
and is expected to continue until 2015. The estimated
number of participants is at least 700 women.
Data handling & statistical methods
At the time of data collection, data is collected on paper
forms and then entered into a Microsoft Access data-
base. Data from each site is stored securely at Menzies
School of Health Research (Darwin) or Baker IDI (Alice
Springs). All statistical analysis will be performed using
the latest available release of Stata software (Stata Cor-
poration, College Station, TX). Rates of diabetes in preg-
nancy (in NT and for Indigenous babies in NT) will be
calculated using the denominators of all NT births and
all births in the NT with Indigenous mothers (using NT
Department of Health Midwives’ Collection birth data).
Analysis will be performed for summary statistics of
rates of diabetes in pregnancy (known pre-existing,
undiagnosed pre-existing and gestational diabetes);
antenatal characteristics of women with DIP (age,
geographic region, gravida/parity etc.); clinical manage-
ment of DIP (use of insulin, oral medications, maternal
hypoglycaemia). Bivariate and multivariate associations
will be determined for demographic, clinical (including
neonatal anthropometric measurements), biochemical
(including cord blood) and socioeconomic variables with
the following key neonatal and maternal outcome vari-
ables: birth weight, gestational age, large for gestational
age, neonatal hyperinsulinaemia (cord blood C-peptideTable 1 Analysis of glucose and lipids at each centre
Test Royal Darwin Hospital (and Darwin Private
Lipids Ortho-Clinical Diagnostics, Fusion 5.1
Glucose Ortho-Clinical Diagnostics, Fusion 5.1>90th centile), neonatal adiposity (fat for gestational age
> 90th centile), pre-eclampsia, birth injury/complication,
adverse labour events, delivery mode and breastfeeding
rates (discharge, 6–8 weeks and 7–9 months). Analyses
will be performed for the whole group and stratified by
ethnic group. After determining bivariate associations
between variables (using Spearman correlations for con-
tinuous variables and two-tailed t-tests for dichotomous
variables), risk factors will be selected for entry into
logistic regression models using the backward selection
method, the outcome variables being the end-points out-
lined above.
Discussion
The aims of the NT Diabetes in Pregnancy Partnership
are to improve clinical care and outcomes of DIP in the
NT, and to improve future health outcomes for both the
mother and her baby through an integrated, multi-
faceted approach. This includes a detailed research com-
ponent, outlined above: the PANDORA Study. This
study should provide answers to three key questions: (i)
rates of diabetes in pregnancy in the NT, including the
high risk Indigenous Australian population of remote
and urban NT; (ii) demographic, clinical, biochemical,
anthropometric and socioeconomic factors that may
contribute to key maternal and neonatal outcomes asso-
ciated with diabetes in pregnancy; and (iii) relevant clin-
ical outcomes for mothers with DIP and their babies.
The results of this study should contribute to policy and
clinical practice guidelines of management of DIP and
follow-up of mother and baby.
The study includes detailed neonatal anthropometric
measurements performed using skinfold measurements,
limb lengths and body circumferences in order to accur-
ately assess neonatal body fat. This method has been
well validated and is reproducible [24,25] with regular
training of research staff. It is notable that although rates
of low birth weight are higher among Indigenous Aus-
tralian babies than the general Australian population
(without DIP), there is increasing evidence that rates of
low birth weight are reducing among Indigenous Austra-
lian babies [26]. In this context, assessment of foetal adi-
posity and its contribution to birth weight is important
in this high risk population. Birth weight alone is not a
sensitive marker of foetal overgrowth in diabetes in
pregnancy [25], and detailed assessment of foetal adipos-
ity is required in order to assess if hyperglycaemia inLaboratory
Hospital) Alice Springs Hospital
Ortho-Clinical Diagnostics, Fusion 5.1
Ortho-Clinical Diagnostics, Fusion 5.1
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ously described in India, that of a “thin-fat baby” [27].
Thus the detailed assessment of neonatal body fat and
cord blood biochemistry in this study should provide
evidence for clinical guidelines in a field where evidence
is currently lacking: the role of neonatal body compos-
ition (relative contributions of adipose tissue mass and
fat free mass to birth weight) in a population at high risk
of both low birth weight (from factors such as malnutri-
tion, maternal smoking) and high birth weight/large for
gestational age due to hyperglycaemia in pregnancy.
The study is likely to also inform the design of future
work to reduce risk of future obesity, diabetes and
cardiovascular disease in both the mothers and babies.
Although better glycaemic management of pregnant
women has been shown to reduce the rate of maternal
and neonatal adverse outcomes in the short term [28];
to date there is no evidence for reduction in the future
risk of diabetes, cardiovascular disease in the mother or
of obesity and type 2 diabetes in the child, by glycaemic
intervention in pregnancy. Observational studies have
reported higher rates of diabetes in children of mothers
with diabetes in pregnancy, and thus reduced levels of
glucose in pregnancy would appear to influence the
child’s future risk of diabetes [13,29,30]. Despite substan-
tial reduction in the risk of macrosomia at birth in the
interventional arm of the Australian Carbohydrate
Intolerance Study in Pregnant Women [9], there was no
difference between the intervention and routine-care
groups in the child’s body mass index at 4–5 years old
[31]. A recent Danish study of non-diabetic adult
offspring born to women with diabetes in pregnancy
(type 1 diabetes and GDM) showed reduced insulin sen-
sitivity and impaired beta cell function [32]. The current
study is designed for ongoing longitudinal follow-up of
both the mothers and babies, and additional funding will
be sought for follow-up.
In conclusion, the NT Diabetes in Pregnancy Partner-
ship and PANDORA Study will have significance for
policy and planning in the NT, as well as in other urban,
rural and remote regions of Australia. Efforts to reduce
risk as early as possible in the life course are crucial in
order to reduce the gap between Indigenous and non-
Indigenous health outcomes in Australia.
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